BioCentury
ARTICLE | Finance

Tiers, some fears

Buysiders expect biotech mid-caps to find favor with generalists in 3Q15

July 13, 2015 7:00 AM UTC

3Q15 Financial Markets Preview

With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in search of different industries or asset classes. Instead, the specialists expect the generalist crowd will continue to move down into the next market cap tier of biotechs. ...